UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
SEC
File Number: 001-42195
CUSIP
Number: 68764Y207
| (Check
One): |
☐ Form
10-K |
☐ Form
20-F |
☐ Form
11-K |
☒ Form
10-Q |
☐ Form
10-D |
| |
☐ Form
N-CEN |
☐ Form
N-CSR |
|
|
|
For
Period Ended: March 31, 2026
| ☐ | Transition
Report on Form 10-K |
| ☐ | Transition
Report on Form 20-F |
| ☐ | Transition
Report on Form 11-K |
| ☐ | Transition
Report on Form 10-Q |
For
the Transition Period Ended: _____________
| Read
Instruction (on back page) Before Preparing Form. Please Print or Type. |
| Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein. |
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I
REGISTRANT
INFORMATION |
| |
| OS
Therapies Incorporated |
Full
Name of Registrant
Not
Applicable |
Former
Name if Applicable
115
Pullman Crossing Road, Suite 103 |
Address
of Principal Executive Office (Street and Number)
Grasonville,
Maryland 21638 |
| City,
State and Zip Code |
PART
II
RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate.)
| ☒ |
(a) |
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
| (b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and |
| (c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III
NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not
be filed within the prescribed time period.
OS
Therapies Incorporated (the “Company”) has determined that it will not be able to file its Quarterly Report on Form 10-Q
for its quarter ended March 31, 2026 (the “Form 10-Q”) by May 15, 2026, the original due date for such filing, without unreasonable
effort or expense, due to delays in compiling and reviewing certain information included in the Form 10-Q resulting primarily from additional
time required for the Company to complete the financial statement close process. The Company expects to file the Form 10-Q within the
extension period of five calendar days, as provided under Rule 12b-25 under the Securities Exchange Act of 1934, as amended.
PART
IV
OTHER
INFORMATION
(1)
Name and telephone number of person to contact in regard to this notification:
Paul
Romness |
|
(410) |
|
297-7793 |
| (Name) |
|
(Area
Code) |
|
(Telephone
Number) |
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s).
☒
Yes ☐ No
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof?
☐ Yes ☒
No
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made.
OS
Therapies Incorporated
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
| Date:
May 15, 2026 |
By: |
/s/ Paul Romness |
| |
|
Paul
Romness |
| |
|
Chief
Executive Officer |
